Premium
Fluorine‐18 labeling of oligonucleotides bearing chemically—modified ribose—phosphate backbones
Author(s) -
Kuhnast Bertrand,
Dolle Frédéric,
Vaufrey Françoise,
Hinnen Françoise,
Crouzel Christian,
Tavitian Bertrand
Publication year - 2000
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/1099-1344(200007)43:8<837::aid-jlcr368>3.0.co;2-2
Subject(s) - phosphodiester bond , deoxyribose , chemistry , oligonucleotide , ribose , sugar phosphates , antisense therapy , chemical modification , phosphate , nucleic acid , stereochemistry , combinatorial chemistry , biochemistry , dna , rna , enzyme , locked nucleic acid , gene
We have recently described the labeling of a natural deoxyribose phosphodiester oligonucleotide with fluorine‐18 (t 1/2 : 109·8 min) and demonstrated its potential for in vivo imaging in a primate PET study. We here report that the methodology employed can be reliably and routinely applied to the most popular chemical modifications: (a) full length internucleosidic phosphorothioate diester bonds deoxyribose oligonucleotides (the modification most favoured by industry for human antisense therapy), (b) hybrid methylphosphonate/phosphodiester internucleosidic bonds deoxyribose oligonucleotides and (c) 2′Methyl modified ribose oligonucleotides. The whole fluorine‐18 labeling procedure allows us to obtain 15 to 21 mCi (0·55 to 0·74 GBq) of pure labeled oligonucleotides (regardless the modification of the sugar phosphate backbone) in 180 minutes with a specific radioactivity of 0·8 to 2 Ci/μmol (30 to 70 GBq/μmol) at the end of synthesis. Copyright © 2000 John Wiley & Sons, Ltd.